ArticleBMC cancer2026
Single-cell transcriptomics reveals MAFB-driven macrophage reprogramming and immune divergence in recurrent glioblastoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is the most aggressive and most common type of primary brain tumor, with poor prognosis despite standard therapies. The mechanisms driving recurrence remain poorly understood. Tumor-associated macrophages (TAM) dominate the GBM microenvironment and promote tumor growth, angiogenesis, and immune suppression, yet their activation states and transcriptional programs are not well defined.
resultsBy integrating large-scale single-cell transcriptomic datasets, we delineate profound immune microenvironmental divergence in recurrent GBM, characterized by the emergence of a distinct CXCL3⁺ tumor-associated macrophage (TAM) population. These CXCL3⁺ TAMs exhibit a robust pro-inflammatory cytokine program, intensified interactions with malignant and immunosuppressive immune cells, and a strong association with poor patient survival. Regulatory network analysis identifies MAFB as the central transcriptional regulator of this TAM state. MAFB is selectively enriched in macrophages, markedly upregulated in recurrent tumors, and strongly correlated with pro-inflammatory gene signatures. Immunohistochemistry and multiplex immunofluorescence further demonstrate an expanded population of MAFB⁺ mesenchymal-like TAMs in recurrent GBM. Depletion of MAFB in patient-derived GBM cells suppresses intracranial tumor growth and prolongs survival in vivo.
conclusionsOur study highlights profound immune remodeling in primary and recurrent GBM. We further define a MAFB-driven CXCL3⁺ macrophage program that shapes the immune landscape of recurrent GBM and underscore this axis as a promising target for microenvironmental reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.